- Home
- SCLXW vs HON Comparison
SCLXW vs HON Comparison
Compare SCLXW & HON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- HON
- Stock Information
- Founded
- SCLXW N/A
- HON 1885
- Country
- SCLXW United States
- HON United States
- Employees
- SCLXW 115
- HON N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- HON Aerospace
- Sector
- SCLXW Health Care
- HON Industrials
- Exchange
- SCLXW Nasdaq
- HON Nasdaq
- Market Cap
- SCLXW N/A
- HON N/A
- IPO Year
- SCLXW N/A
- HON N/A
- Fundamental
- Price
- SCLXW $0.05
- HON $196.60
- Analyst Decision
- SCLXW
- HON Buy
- Analyst Count
- SCLXW 0
- HON 13
- Target Price
- SCLXW N/A
- HON $238.17
- AVG Volume (30 Days)
- SCLXW 4.0K
- HON 5.1M
- Earning Date
- SCLXW 03-07-2025
- HON 04-29-2025
- Dividend Yield
- SCLXW N/A
- HON 2.34%
- EPS Growth
- SCLXW N/A
- HON 2.83
- EPS
- SCLXW N/A
- HON 8.71
- Revenue
- SCLXW $55,152,000.00
- HON $38,498,000,000.00
- Revenue This Year
- SCLXW N/A
- HON $5.86
- Revenue Next Year
- SCLXW N/A
- HON $4.49
- P/E Ratio
- SCLXW N/A
- HON $22.57
- Revenue Growth
- SCLXW 22.02
- HON 5.01
- 52 Week Low
- SCLXW $0.18
- HON $179.36
- 52 Week High
- SCLXW $0.18
- HON $242.77
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- HON 44.21
- Support Level
- SCLXW N/A
- HON $192.51
- Resistance Level
- SCLXW N/A
- HON $202.36
- Average True Range (ATR)
- SCLXW 0.00
- HON 8.09
- MACD
- SCLXW 0.00
- HON -0.32
- Stochastic Oscillator
- SCLXW 0.00
- HON 46.53
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.